13 withdrawn. 13 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Withdrawn 13 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Hepatitis, Chronic: new trials by email Literature Review of Hepatitis, Chronic trials Research Report on Hepatitis, Chronic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD) Ombitasvir/paritaprevir/ritonavir - Chronic Hepatitis C Virus | Phase 3 | Withdrawn | AbbVie | 2016-09-01 | 2016-12-05 | |
| Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis Paeoniflorin + phosphatidylcholine or silymarin, Phosphatidylcholine or silymarin - Hepatitis, Autoimmune | Phase 3 | Withdrawn | Xiaoli Fan | 2016-08-01 | 2017-07-13 | |
| The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III) Peginterferon alfa-2a, Ribavirin, TCM-700C - Chronic Hepatitis C | Phase 3 | Withdrawn | TCM Biotech International Corp. | 2015-06-01 | 2017-04-28 | |
| Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) Boceprevir, Peginterferon Alfa-2b 1.5 mcg/kg/week, Ribavirin - Chronic Hepatitis C | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2014-05-01 | 2015-09-09 | |
| Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin - Chronic Hepatitis C | Phase 3 | Withdrawn | ANRS, Emerging Infectious Diseases | 2014-04-01 | 2017-07-12 | |
| Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C Legalon® SIL (Silibinin), Pegylated interferon alfa2b, Ribavirin - Hepatitis C, Chronic | Phase 2 / Phase 3 | Withdrawn | Rottapharm | 2013-08-01 | 2015-03-05 | |
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients BI 201335, ribavirin, BI 207127 - Hepatitis C, Chronic | Phase 3 | Withdrawn | Boehringer Ingelheim | 2013-05-01 | 2014-01-23 | |
| Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034) Boceprevir, Peginterferon alpha-2b, Ribavirin - Chronic Hepatitis C | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2013-01-28 | 2021-01-29 | |
| A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection PegIFN/RBV, BI 201335 - Hepatitis C, Chronic | Phase 3 | Withdrawn | Boehringer Ingelheim | 2012-09-01 | 2013-02-26 | |
| 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C pegylated interferon alpha 2a + ribavirin - Chronic Hepatitis C | Phase 3 | Withdrawn | Federico II University | 2012-05-01 | 2012-03-19 | |
| Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation Nabi-HB - Hepatitis B, Chronic | Phase 3 | Withdrawn | Biotest Pharmaceuticals Corporation | 2010-04-01 | 2016-01-18 | |
| A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER) peginterferon alfa-2a [Pegasys], ribavirin [Copegus] - Hepatitis C, Chronic | Phase 3 | Withdrawn | Hoffmann-La Roche | 2009-12-01 | 2016-11-02 | |
| Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test 13C Methacetin Breath Test (BreathID) - Chronic Hepatitis B | Phase 2 / Phase 3 | Withdrawn | Hadassah Medical Organization | 2012-08-28 |
Hepatitis C, Chronic (10) · Hepatitis B, Chronic (2) · Hepatitis (1) · Hepatitis C (1) · Hepatitis, Autoimmune (1) · Kidney Failure, Chronic (1)
Digestive System Diseases (13) · Liver Diseases (13) · Blood-Borne Infections (12) · Chronic Disease (12) · Communicable Diseases (12) · Disease Attributes (12) · Hepatitis (12) · Hepatitis, Viral, Human (12) · Infections (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Virus Diseases (12) · Flaviviridae Infections (10) · RNA Virus Infections (10)
Ribavirin (8) · peginterferon alfa-2b (4) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (2) · faldaprevir (2) · peginterferon alfa-2a (2) · Phosphatidylcholines (1) · Silybin (1) · Silymarin (1) · Vitamin D (1) · deleobuvir (1) · hepatitis B hyperimmune globulin (1) · ombitasvir (1) · peoniflorin (1) · telaprevir (1)
Boehringer Ingelheim (2) · Merck Sharp & Dohme LLC (2) · ANRS, Emerging Infectious Diseases (1) · AbbVie (1) · Biotest Pharmaceuticals Corporation (1) · Federico II University (1) · Hadassah Medical Organization (1) · Hoffmann-La Roche (1) · Rottapharm (1) · TCM Biotech International Corp. (1) · Xiaoli Fan (1)
China (2) · Egypt (2) · Australia (1) · Israel (1) · Italy (1) · Spain (1) · Sweden (1) · Taiwan (1)
Arnaud Fontanet, MD, PhD (1) · Gamal Esmat, MD (1) · Gamal Esmat, MD, PhD (1) · Guglielmo Borgia, Professor (1) · I-Shyan Sheen, MD (1) · Koji Kato, MD (1) · Lai Wei, MD (1) · Li Yang, MD (1) · Samer El-Kamary, MD (1) · Shailesh Chavan, MD (1)